BioMarin posts first $1 billion quarter, sets VOXZOGO PDUFA date for hypochondroplasiaNov 2Quarterly updateBiomarin Pharmaceutical Incvosoritide
Zevra reports Q2 2026 results as MIPLYFFA revenue grows and EU review continuesAug 5Quarterly updatearimoclomolZevra Therapeutics, Inc.